EGFR and cancer: In addition to the metabolic feature of UCK2 which has been employed for cancer treatment, our recent study has demonstrated that UCK2 can non-metabolically activating EGFR-AKT signaling to promote HCC progression, which may provide novel UCK2-based therapeutic strategies for cancer treatment.